Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status

被引:198
作者
Lissoni, P [1 ]
Barni, S [1 ]
Mandalà, M [1 ]
Ardizzoia, A [1 ]
Paolorossi, F [1 ]
Vaghi, M [1 ]
Longarini, R [1 ]
Malugani, F [1 ]
Tancini, G [1 ]
机构
[1] S Gerardo Hosp, Div Radiat Oncol, I-20052 Milan, Italy
关键词
chemotherapy toxicity; melatonin; pineal gland; supportive care;
D O I
10.1016/S0959-8049(99)00159-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Melatonin (MLT) has been proven to counteract chemotherapy toxicity, by acting as an anti-oxidant agent, and to promote apoptosis of cancer cells, so enhancing chemotherapy cytotoxicity. The aim of this study was to evaluate the effects of concomitant MLT administration on toxicity and efficacy of several chemotherapeutic combinations in advanced cancer patients with poor clinical status. The study included 250 metastatic solid tumour patients (lung cancer, 104; breast cancer, 77; gastrointestinal tract neoplasms, 42; head and neck cancers, 27), who were randomised to receive MLT (20 mg/day orally every day) plus chemotherapy, or chemotherapy alone. Chemotherapy consisted of cisplatin (CDDP) plus etoposide or gemcitabine alone for lung cancer, doxorubicin alone, mitoxantrone alone or paclitaxel alone for breast cancer, 5-FU plus folinic acid for gastro-intestinal tumours and 5-FU plus CDDP for head and neck cancers. The 1-year survival rate and the objective tumour regression rate were significantly higher in patients concomitantly treated with MLT than in those who received chemotherapy (CT) alone (tumour response rate: 42/124 CT + MLT versus 19/126 CT only, P<0.001; 1-year survival: 63/124 CT + MLT versus 29/126 CT only, P<0.001). Moreover, the concomitant administration of MLT significantly reduced the frequency of thrombocytopenia, neurotoxicity, cardiotoxicity, stomatitis and asthenia. This study indicates that the pineal hormone MLT may enhance the efficacy of chemotherapy and reduce its toxicity, at least in advanced cancer patients of poor clinical status. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1688 / 1692
页数:5
相关论文
共 28 条
[1]  
ABO T, 1981, J IMMUNOL, V126, P1360
[2]   MELATONIN [J].
ARENDT, J .
CLINICAL ENDOCRINOLOGY, 1988, 29 (02) :205-229
[3]  
BARTSCH C, 1992, CANCER J - FRANCE, V5, P194
[4]  
Bartsch Christian, 1995, In Vivo (Attiki), V9, P305
[5]  
Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186
[6]   Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21(WAF1/CIP1) via C/EBP beta [J].
Chinery, R ;
Brockman, JA ;
Peeler, MO ;
Shyr, Y ;
Beauchamp, RD ;
Coffey, RJ .
NATURE MEDICINE, 1997, 3 (11) :1233-1241
[7]  
Cos S, 1998, CANCER RES, V58, P4383
[8]  
Di Bella L, 1979, Prog Brain Res, V52, P475
[9]  
JANKOVIC BD, 1994, ANN NY ACAD SCI, V741, P1
[10]  
LISSONI P, 1986, CANCER-AM CANCER SOC, V57, P837, DOI 10.1002/1097-0142(19860215)57:4<837::AID-CNCR2820570425>3.0.CO